AFFY:OTC-Affymax, Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.06

Change

-0.02 (-26.12)%

Market Cap

USD 3.38M

Volume

0.12M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Company Website : http://www.affymax.com

Address : 630 Fifth Avenue, New York, NY, United States, 10020

Employees : 2

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.80

52 Week High : 0.26

Short Ratio : 2.35

52 Week Low : 0.02

Shorted Shares : 18,481,851

200 Day Moving Average : 0.12

Shorted Shares Previous Month : 15,826,827

50 Day Moving Average : 0.08

Short Percentage : 49.00%

Shares Held by Institutions : 0%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-13 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

+2.19 (+2.85%)

 USD174.16B 25.58 2.92
CMXHF CSL Limited

+4.81 (+2.28%)

 USD97.60B 36.05 21.59
CSLLY CSL Limited

+2.25 (+2.13%)

 USD95.65B 36.12 21.59
GNMSF Genmab A/S

+5.30 (+1.44%)

 USD23.78B 26.79 2.99
SBMFF Sino Biopharmaceutical Limited

N/A

 USD20.43B 45.43 2.77
SBHMY Sino Biopharmaceutical Limited

N/A

 USD19.75B 45.25 2.77
UCBJY UCB SA

+0.21 (+0.45%)

 USD17.44B 20.24 14.59
UCBJF UCB SA

N/A

 USD17.41B 21.41 14.59
PPTDF PeptiDream Inc

N/A

 USD5.61B 140.32 0.73
AKABY ALK-Abelló A/S

N/A

 USD4.74B 444.19 11.84

ETFs Containing AFFY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 135.00% 83% B 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 135.00% 83% B 85% B
Trailing 12 Months  
Capital Gain 103.67% 61% D- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 103.67% 63% D 65% D
Trailing 5 Years  
Capital Gain -29.77% 47% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.77% 47% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain 8.99% 39% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.99% 38% F 47% F
Risk Return Profile  
Volatility (Standard Deviation) 77.46% 53% F 37% F
Risk Adjusted Return 11.61% 35% F 37% F
Market Capitalization 3.38M 30% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.01 85% B 92% A-
Price/Book Ratio 0.56 91% A- 81% B-
Price / Cash Flow Ratio -0.05 25% F 56% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 111.59% 99% A+ 99% A+
Return on Invested Capital -456.89% 5% F 3% F
Return on Assets -228.91% 18% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.35 38% F 28% F
Short Percent 49.35% 4% F 9% F
Beta 2.80 9% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.